Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention – American College of Cardiology
Contact: Nicole Napoli , nnapoli@acc.org, 202-669-1465 People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y 12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented